Latest Breaking News On - கீந் தொழில்நுட்பங்கள் - Page 1 : comparemela.com
American Gene Technologies HIV Cure Clinical Trial Shows Additional Progress with No Serious Adverse Events (SAEs)
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
American Gene Technologies Appoints Dr Robert R Redfield as Special Advisor to the CEO
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
Nachricht vom 23.07.2021 | 07:01
Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
Lonza Group AG / Key word(s): Half Year Results
23-Jul-2021 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Ad Hoc Release Pursuant to Art. 53 Listing Rules
In H1 2021, Lonza continued its strong performance with 14.7%
1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19
Continued focus on growth CAPEX investments, supported by strong business pipeline
Expanded collaborations to support COVID-19 programs including Moderna
Divestment of Specialty Ingredients business completed on 1 July 2021
EQS-Adhoc: Lonza .
EQS-Adhoc: Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
vom 23.07.2021, 07:01 Uhr
Bild: pixabay.com
EQS Group-Ad-hoc: Lonza Group AG / Key word(s): Half Year Results
Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
23-Jul-2021 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Ad Hoc Release Pursuant to Art. 53 Listing Rules
In H1 2021, Lonza continued its strong performance with 14.7%
1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19
Continued focus on growth CAPEX investments, supported by strong business pipeline
EQS-Adhoc: Lonza Group AG: Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
23-Jul-2021 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Ad Hoc Release Pursuant to Art. 53 Listing Rules
In H1 2021, Lonza continued its strong performance with 14.7%
1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19
Continued focus on growth CAPEX investments, supported by strong business pipeline
Expanded collaborations to support COVID-19 programs including Moderna
vimarsana © 2020. All Rights Reserved.